List of questions

A
AbbVie AB
  • 1410

    How can we improve the identification of treatment benefit/ risk profiles for different patient groups in Immune Mediated Inflammatory Diseases (IMID)?


    For example, are there novel approaches for creating a fingerprint for response/non-response to JAK-inhibitors/IL-23 inhibitors?


Astrazeneca
  • 1448

    In the area of cardiovascular and metabolic disease where are the best opportunities for personalized healthcare considering the combination of medical need with opportunity to find useful biomarkers? Medical need driven by partial drug responses in patient cohorts. Biomarker identification driven by feasibility of technology


    At AZ we are implementing a personalized approach for all Projects in the portfolio, including cardiovascular, metabolic and respiratory disease. We are looking to optimise the identification of biomarkers for future CDx use in these non-oncoloy areas. Key to success is to identify disease subgroups by biomarkers.


D
Double Bond Pharmaceutical AB
  • 1441

    Biomarkers: How to choose from the industry perspective what biomarker and method of measurement to go for?


    Known molecules that anyone can measure (i.e. in any clinic) - in this case how to ensure the quality of result if the methods are different and performed in different hands? Or new molecules and measurement methods that we develop and perform ourselves, and thus ensuring quality - how to make everyone turn to us and not try to do own in-house versions themselves (quality question again).

  • 1442

    Collaboration: How can the academy collaborate with small life science companies - a natural meeting forum or platform is needed where one can advertise the needs and find relevant and interested collaborative research groups.



I
Illumina
  • 1440

    How can awareness and knowledge of precision medicine be increased in the general population and in the healthcare system? What can we, from a technology provider standpoint, contribute with?


    We live in truly exciting times. Over the last years technology has advanced at a rapid pace making it easier, faster and more cost-effective to determine the genetic makeup of an individual than ever before. As such, we are getting to the point where precision medicine – tailoring treatment to the unique characteristics of the individual, such as his or her genetic composition – has the potential to be broadly applied. Naturally, introduction of this model and implementation of genomics for routine use bring a number of significant changes to the healthcare system. Of course, these changes lead to questions and concerns from the general population and from the healthcare workers, and these need to be addressed in a clear and informative manner. What can we as a supplier of technology contribute with to inform what precision medicine is and is not, what the possibilities are and what it cannot do and when it is applicable and beneficial?

    General population:
    • How familiar is the general population with precision medicine?
    • How can awareness in this group be raised? Which activities are needed?
    • What are the main concerns and what information is required to alleviate these? Would real-world examples of precision medicine, for example, be beneficial?
    • How can we, as a technology provider, assist?

    Healthcare system:
    • How can members of the healthcare system, who might be working with precision medicine in the future, be educated to increase knowledge? Which activities would have most impact?
    • How can information about the possibilities and risks be disseminated?
    • What information is crucial, e.g. cost-benefit data?
    • Given the multi-disciplinary nature of this topic, how can we work together in the best possible way?
    • What can we, as a technology company, help with?


O
Olink Proteomics
  • 1443

    Proteomics in Precision Medicine – opportunities and challenges


    We would like to discuss with the research community and get your input on the opportunities and challenges for proteomics in precision medicine. What are your views on the different areas where proteomics could be of use for example multi-omics, patient stratification, pathophysiology, drug target, surrogate endpoint and wellness? Are there additional areas within precision medicine where proteomic analysis is needed?


P
PCG Clinical Services
  • 1403

    How important will standardization of data and interoperability be to the development, use, and understanding of precision medicine and will this be even more important than conventional medicine?


    Today there are so many silos in between pre-clinical, clinical, and post-market research and development and within each area as well. There are very few standards that spread across all areas and often researchers don’t even have access to all three areas and thus lack a full understanding of the molecule and/or drug. Thick Data, or data that is collected via qualitative, ethnographic research methods, is often not quantitative or easily measured. Personalized medicine, especially Advance Cell Therapies, may have variable amounts and types of data and perhaps even less than conventional medicines. Which means that all data (qualitative and quantitative) collected must be understood to develop a full understanding of safety and efficacy.


Pharmacolog i Uppsala AB
  • 1439

    Pharmacolog R/D program focuses on technology development for analyzing biological liquids like plasma within seconds to identify different biomarkers, drug concentrations like cytostatic and antibiotics, why we want to address our interest of finding co-operation with research groups and/or industrial companies working with biomarkers and antibodies that can be applied to our technology within our research programs.


    Pharmacolog AB is an Uppsala based company listed on Aktietorget (PHLOG) with focus to develop new innovative products for safe and effective drug delivery focused on intravenous drugs in cancer care and other disciplines where dangerous drugs are used like antibiotics.
    Our existing product DrugLog is an ease of use instrument sold to Pharmacies and clinical wards to secure that the reconstitution of intravenous drugs validates that the right drug with right concentration reaches the right patient.
    Our vison is to develop new solutions using photo spectrometry to allow bed site dose rate adaptation during the infusion treatment, where patient’s biological and physical response parameters are taken into consideration.
    www.pharmacolog.com


R
Roche AB
  • 1380

    Validation of NGS based tests?


    NGS analyses often provide varying results. Validation is required for robust results.

  • 1381

    BIoinformatics and genetics?


    NGS generates large amounts of data that needs interpretation.

  • 1382

    Capacity for clinical sequencing and report generation?


    Introduction of NGS based sequencing into the clinic requires capacity beyond the traditional research group setting


T
Thermofisher Scientific
  • 1406

    English: There are only a few companion diagnostic products registered today ( 18 ?). considering the resources and investment in the field, it seems to be quite low success rate. How could this situation be improved? Could there be a conceptual miscalculation in current processes?

    Svenska: Det finns i dag xx (jag tror xx är 18) godkända companion diagnostics produkter. Ett väldigt lågt antal med tanke på hur mycket resurser som är satsat. Är det möjligt att förbättra situationen eller är det en konceptfel?


    Personalized medicine is an evolving field of medicine in which treatments are tailored to the individual patient. You may have a condition, for example, that is caused by a mutation in your genes. With advances in personalized medicine, you might be prescribed a medication that targets that specific mutation.

  • 1407

    English: What would be the regulatory and technical requirements for approval of a “precision medicine” assay? Would it be the same type of requirements as for current diagnostic tests? (PPV, NPV, Sen., Spec., etc. )

    Svenska: Vad kommer det att finnas för krav för godkännandet av nya ”precision medicin” tester? Ska det vara samma hårda specifikationer som gäller ett diagnostiskt test? (PPV,NPV, Precision; sens, spec. etc)


    Companion diagnostics can:
    •identify patients who are most likely to benefit from a particular therapeutic product;
    •identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or
    •monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.
    So the question is, do we need as high sensitivity and specificity for a companion diagnostic biomaker as for a classic diagnostic biomarker?

  • 1408

    English: How could you promote the value of a diagnostic test which can reduce the burden on the healthcare budget? ( new price models, different reimbursement? )

    Svenska: Hur skulle man kunna ”uppgradera” värdet av ett diagnostisk test som kan minska bördan på vårdbudgeten? ( nya prismodeller och återbäringssytem)


    www.mdpi.com/2075-4426/2/4/257/pdf

  • 1409

    English: Is precision medicine about advanced testing/treatment handled only by specialist or could GPs and the patient be included in the concept? (PoC, OTC, etc.)

    Svenska: Kommer precision medicin att handla om vad specialister gör eller kan det vara primärvårdsläkare och patienter också? ( PoC och OTC som en del av kedjan)


    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508182/
    https://bmcmedgenomics.biomedcentral.com/articles/10.1186/s12920-016-0183-8


U
Uppsala Monitoring Centre
  • 1452

    How can we bridge potential individual-level risk factors for adverse drug reactions identified in anonymous spontaneous reports to be tested in a clinical setting?


    Precision medicine is most often considered in the context of using genetic diversity to predict those patients who are most likely to respond favorably to medicines; however, it is also true that it can be used to predict those patients who are most likely to respond unfavorably, or in other words, to experience adverse drug reactions. Individuals experiencing harms from medicines are oftentimes “outliers” at the population-level; however, they can inform on risk factors for harms at the individual-level. There are several examples that illustrate an underlying genetic predisposition to ADRs, including the HLA allele B*1502 as a marker for carbamazepine-induced Stevens Johnson syndrome and HLA DQB1*06:02 as a potential marker for Pandemrix-induced narcolepsy.